13D Filing: OrbiMed Advisors and Ascendis Pharma A/S (ASND)

Page 4 of 14

Page 4 of 14 – SEC Filing

SCHEDULE 13D
CUSIP No.  04351P101
Page 4 of 16 Pages
1
NAME OF REPORTING PERSONS
OrbiMed Capital GP V LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) o
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
AF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
4,198,291
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
4,198,291
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,198,291
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
12.9%*
14
TYPE OF REPORTING PERSON (See Instructions)
OO
______________
* This percentage is calculated based upon 32,502,555 of the Issuer’s Ordinary Shares outstanding (including any such Ordinary Shares represented by ADSs (as defined below)), as set forth in the Issuer’s Form 6-K dated June 15, 2017 and filed with the SEC (as defined below) on June 15, 2017.

Follow Ascendis Pharma A/S

Page 4 of 14